Insider · CIK 0001665133

Nuechterlein Carole

Reports to the SEC for 6 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001665133

Forms 4 and 5

Insider transactions

23 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-25	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,860 sh	—	—	5,860
2025-06-25	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,860 sh	—	—	5,860
2024-06-27	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+60K sh	—	—	60,000
2024-02-28	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+4,411 sh	—	—	4,411
2024-02-27	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2023-10-25	ALGSAligos Therapeutics, Inc.P Purchase	Director	PPurchase	+7.93M sh	$0.76	+$6M	11,025,941
2023-10-25	ALGSAligos Therapeutics, Inc. · Warrant (Right to Buy)P Purchase	Director	PPurchase	+3.97M sh	$0.13	+$496K	3,966,800
2023-07-20	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-06-23	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2022-06-02	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+11.9K sh	—	—	11,918
2021-10-28	TRDAEntrada Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+23.6K sh	—	—	23,522
2021-06-17	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director	CConversion	+2.15M sh	—	—	2,145,991
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director	CConversion	+663K sh	—	—	2,808,790
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director	CConversion	+284K sh	—	—	3,092,340
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director	CConversion	−2.15M sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director	CConversion	−663K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-2 Preferred StockC Conversion	Director	CConversion	−284K sh	—	—	0
2020-06-22	TPSTTempest Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2019-06-20	TPSTTempest Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2019-01-15	TPSTTempest Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2016-02-10	AveXis, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+18.1K sh	—	—	18,111
2016-02-10	AveXis, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,385 sh	—	—	8,385

Recent filings

Accepted (ET)
Jun 294
Nuechterlein Carole0001610717-26-000301
SEC(opens sec.gov)
Jun 264
Nuechterlein Carole0001610717-25-000259
SEC(opens sec.gov)
Jun 284
Nuechterlein Carole0001610717-24-000371
SEC(opens sec.gov)
Feb 284
Nuechterlein Carole0001610717-24-000095
SEC(opens sec.gov)
Oct 274
Nuechterlein Carole0001610717-23-000320
SEC(opens sec.gov)
Jul 214
Nuechterlein Carole0001610717-23-000210
SEC(opens sec.gov)
Jun 274
Nuechterlein Carole0001567619-22-013388
SEC(opens sec.gov)
Jun 64
Nuechterlein Carole0001104659-22-068500
SEC(opens sec.gov)
Nov 14
Nuechterlein Carole0001104659-21-132480
SEC(opens sec.gov)
Jun 174
Nuechterlein Carole0001567619-21-012335
SEC(opens sec.gov)
Oct 204
Nuechterlein Carole0001567619-20-018003
SEC(opens sec.gov)
Jun 234
Nuechterlein Carole0001544227-20-000035
SEC(opens sec.gov)
Jun 214
Nuechterlein Carole0001209191-19-038486
SEC(opens sec.gov)

Companies

Address

C/O FREENOME, INC 51 ASTOR PLACE, 10TH FLOOR

NEW YORK, NY, 10003